Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Anti-PSMA/CD3 Bispecific Antibody Delivery And Anti-Tumor Activity Using A Polymeric Depot Formulation.

Leconet W, Liu H, Guo M, Le Lamer-Déchamps S, Molinier C, Kim S, Vrlinic T, Oster M, Liu F, Navarro V, Batra JS, Lopez-Noriega A, Grizot S, Bander NH.

Mol Cancer Ther. 2018 Jun 11. pii: molcanther.1138.2017. doi: 10.1158/1535-7163.MCT-17-1138. [Epub ahead of print]

PMID:
29891487
2.

Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.

Miyahira AK, Pienta KJ, Morris MJ, Bander NH, Baum RP, Fendler WP, Goeckeler W, Gorin MA, Hennekes H, Pomper MG, Sartor O, Tagawa ST, Williams S, Soule HR.

Prostate. 2018 May 1. doi: 10.1002/pros.23642. [Epub ahead of print] Review.

PMID:
29717499
3.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.

McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL.

J Immunother Cancer. 2016 Dec 20;4:92. doi: 10.1186/s40425-016-0198-x. eCollection 2016.

4.

Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment.

Nguyen DP, Xiong PL, Liu H, Pan S, Leconet W, Navarro V, Guo M, Moy J, Kim S, Ramirez-Fort MK, Batra JS, Bander NH.

Mol Cancer Res. 2016 Nov;14(11):1045-1053. Epub 2016 Jul 25.

5.

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.

Milowsky MI, Galsky MD, Morris MJ, Crona DJ, George DJ, Dreicer R, Tse K, Petruck J, Webb IJ, Bander NH, Nanus DM, Scher HI.

Urol Oncol. 2016 Dec;34(12):530.e15-530.e21. doi: 10.1016/j.urolonc.2016.07.005. Epub 2016 Oct 17.

6.

Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic Malignancies: Implications for PSMA-targeted Therapy.

Wernicke AG, Kim S, Liu H, Bander NH, Pirog EC.

Appl Immunohistochem Mol Morphol. 2017 Apr;25(4):271-276. doi: 10.1097/PAI.0000000000000297.

PMID:
26862945
7.

Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling.

Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR, Bander NH, Larson SM, Zanzonico PB, Osborne JR.

EJNMMI Res. 2016 Dec;6(1):7. doi: 10.1186/s13550-016-0164-0. Epub 2016 Jan 22.

8.

Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma.

Crowley MJ, Scognamiglio T, Liu YF, Kleiman DA, Beninato T, Aronova A, Liu H, Jhanwar YS, Molina A, Tagawa ST, Bander NH, Zarnegar R, Elemento O, Fahey TJ 3rd.

J Clin Endocrinol Metab. 2016 Mar;101(3):981-7. doi: 10.1210/jc.2015-4021. Epub 2016 Jan 15.

PMID:
26771706
9.

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.

Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gönen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne JR, Lewis JS, Reuter VE, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ.

Clin Cancer Res. 2015 Dec 1;21(23):5277-85. doi: 10.1158/1078-0432.CCR-15-0552. Epub 2015 Jul 14.

10.

Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.

Pandit-Taskar N, O'Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M, Smith-Jones P, Bander NH, Scher HI, Larson SM, Morris MJ.

EJNMMI Res. 2015 Apr 29;5:28. doi: 10.1186/s13550-015-0104-4. eCollection 2015.

11.

Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.

Vallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM, Bander NH, Goldsmith SJ.

Curr Radiopharm. 2016;9(1):44-53. Review.

PMID:
25771365
12.

Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.

Klute K, Nackos E, Tasaki S, Nguyen DP, Bander NH, Tagawa ST.

Onco Targets Ther. 2014 Dec 3;7:2227-36. doi: 10.2147/OTT.S46887. eCollection 2014. Review.

13.

The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.

Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, MacDonald TY, Fontugne J, Erho N, Vergara IA, Ghadessi M, Davicioni E, Jenkins RB, Palanisamy N, Chen Z, Nakagawa S, Hirose T, Bander NH, Beltran H, Fox AH, Elemento O, Rubin MA.

Nat Commun. 2014 Nov 21;5:5383. doi: 10.1038/ncomms6383.

14.

⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.

Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM.

Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2093-105. doi: 10.1007/s00259-014-2830-7. Epub 2014 Aug 21.

16.

Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow.

Gakhar G, Navarro VN, Jurish M, Lee GY, Tagawa ST, Akhtar NH, Seandel M, Geng Y, Liu H, Bander NH, Giannakakou P, Christos PJ, King MR, Nanus DM.

PLoS One. 2013 Dec 27;8(12):e85143. doi: 10.1371/journal.pone.0085143. eCollection 2013.

17.

Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.

Wernicke AG, Varma S, Greenwood EA, Christos PJ, Chao KS, Liu H, Bander NH, Shin SJ.

APMIS. 2014 Jun;122(6):482-9. doi: 10.1111/apm.12195. Epub 2013 Dec 5.

PMID:
24304465
18.

A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.

Osborne JR, Green DA, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis JS, Christos P, Larson SM, Bander NH, Scherr DS.

J Urol. 2014 May;191(5):1439-45. doi: 10.1016/j.juro.2013.10.041. Epub 2013 Oct 14.

19.

Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.

Tagawa ST, Akhtar NH, Nikolopoulou A, Kaur G, Robinson B, Kahn R, Vallabhajosula S, Goldsmith SJ, Nanus DM, Bander NH.

Front Oncol. 2013 Aug 26;3:214. doi: 10.3389/fonc.2013.00214. eCollection 2013.

20.

Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell capture.

Huang C, Santana SM, Liu H, Bander NH, Hawkins BG, Kirby BJ.

Electrophoresis. 2013 Nov;34(20-21):2970-9. doi: 10.1002/elps.201300242. Epub 2013 Oct 9.

21.

Antibody-drug conjugate target selection: critical factors.

Bander NH.

Methods Mol Biol. 2013;1045:29-40. doi: 10.1007/978-1-62703-541-5_2. Review.

PMID:
23913139
22.

Enrichment of prostate cancer cells from blood cells with a hybrid dielectrophoresis and immunocapture microfluidic system.

Huang C, Liu H, Bander NH, Kirby BJ.

Biomed Microdevices. 2013 Dec;15(6):941-8. doi: 10.1007/s10544-013-9784-6.

23.

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM.

Clin Cancer Res. 2013 Sep 15;19(18):5182-91. doi: 10.1158/1078-0432.CCR-13-0231. Epub 2013 May 28.

24.

Antibody-drug conjugate technology development for hematologic disorders.

Bander NH, Czuczman MS, Younes A.

Clin Adv Hematol Oncol. 2012 Aug;10(8 Suppl 10):1-16.

PMID:
23072775
25.

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.

Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA.

Cancer Discov. 2012 Nov;2(11):995-1003. doi: 10.1158/2159-8290.CD-12-0222. Epub 2012 Oct 23.

26.

Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.

Valencia PM, Pridgen EM, Perea B, Gadde S, Sweeney C, Kantoff PW, Bander NH, Lippard SJ, Langer R, Karnik R, Farokhzad OC.

Nanomedicine (Lond). 2013 May;8(5):687-98. doi: 10.2217/nnm.12.134. Epub 2012 Oct 17.

27.

Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.

Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, Gleghorn JP, Santana SM, Liu H, Smith JP, Navarro VN, Tagawa ST, Bander NH, Nanus DM, Giannakakou P.

PLoS One. 2012;7(4):e35976. doi: 10.1371/journal.pone.0035976. Epub 2012 Apr 27. Erratum in: PLoS One. 2012;7(7): doi/10.1371/annotation/9d3d22ed-dc5a-4484-9254-1584864f4aac.

28.

Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.

Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S.

Sci Transl Med. 2012 Apr 4;4(128):128ra39. doi: 10.1126/scitranslmed.3003651.

29.

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity.

Haffner MC, Laimer J, Chaux A, Schäfer G, Obrist P, Brunner A, Kronberger IE, Laimer K, Gurel B, Koller JB, Seifarth C, Zelger B, Klocker H, Rasse M, Doppler W, Bander NH.

Mod Pathol. 2012 Aug;25(8):1079-85. doi: 10.1038/modpathol.2012.66. Epub 2012 Mar 30.

30.

Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.

Santana SM, Liu H, Bander NH, Gleghorn JP, Kirby BJ.

Biomed Microdevices. 2012 Apr;14(2):401-7. doi: 10.1007/s10544-011-9616-5.

31.

Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme.

Wernicke AG, Edgar MA, Lavi E, Liu H, Salerno P, Bander NH, Gutin PH.

Arch Pathol Lab Med. 2011 Nov;135(11):1486-9. doi: 10.5858/arpa.2010-0740-OA.

PMID:
22032578
32.

Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.

Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, Lewis JS, Grimm J.

J Nucl Med. 2011 Oct;52(10):1608-15. doi: 10.2967/jnumed.111.092098. Epub 2011 Sep 9.

33.

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.

Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P.

Cancer Res. 2011 Sep 15;71(18):6019-29. doi: 10.1158/0008-5472.CAN-11-1417. Epub 2011 Jul 28.

34.

Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate.

Nakajima T, Mitsunaga M, Bander NH, Heston WD, Choyke PL, Kobayashi H.

Bioconjug Chem. 2011 Aug 17;22(8):1700-5. doi: 10.1021/bc2002715. Epub 2011 Jul 27.

35.

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.

Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL.

Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9578-82. doi: 10.1073/pnas.1106383108. Epub 2011 May 23.

36.

89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS.

J Nucl Med. 2010 Aug;51(8):1293-300. doi: 10.2967/jnumed.110.076174. Epub 2010 Jul 21.

37.

Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.

Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH.

Prostate. 2010 Sep 1;70(12):1286-94. doi: 10.1002/pros.21164.

PMID:
20623630
38.

ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation.

Wang AZ, Yuet K, Zhang L, Gu FX, Huynh-Le M, Radovic-Moreno AF, Kantoff PW, Bander NH, Langer R, Farokhzad OC.

Nanomedicine (Lond). 2010 Apr;5(3):361-8. doi: 10.2217/nnm.10.6.

39.

Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.

Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH.

Cancer. 2010 Feb 15;116(4 Suppl):1075-83. doi: 10.1002/cncr.24795.

40.

Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.

Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, Nanus DM, Giannakakou PA, Kirby BJ.

Lab Chip. 2010 Jan 7;10(1):27-9. doi: 10.1039/b917959c. Epub 2009 Nov 16.

41.

Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers.

Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Mühlmann G, Ofner D, Zelger B, Ensinger C, Yang XJ, Geley S, Margreiter R, Bander NH.

Hum Pathol. 2009 Dec;40(12):1754-61. doi: 10.1016/j.humpath.2009.06.003. Epub 2009 Aug 27.

PMID:
19716160
42.

Editorial comment.

Bander NH.

J Urol. 2009 Sep;182(3):947-8. doi: 10.1016/j.juro.2009.05.131. Epub 2009 Jul 17. No abstract available.

PMID:
19616227
43.
44.

Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.

Wang AZ, Bagalkot V, Vasilliou CC, Gu F, Alexis F, Zhang L, Shaikh M, Yuet K, Cima MJ, Langer R, Kantoff PW, Bander NH, Jon S, Farokhzad OC.

ChemMedChem. 2008 Sep;3(9):1311-5. doi: 10.1002/cmdc.200800091. No abstract available.

45.

Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2.

Goodman OB Jr, Barwe SP, Ritter B, McPherson PS, Vasko AJ, Keen JH, Nanus DM, Bander NH, Rajasekaran AK.

Int J Oncol. 2007 Nov;31(5):1199-203.

PMID:
17912448
46.

Active and passive immunotherapy: vaccines and antibodies.

Oosterwijk E, Divgi C, Bander NH.

BJU Int. 2007 May;99(5 Pt B):1301-4. Review. No abstract available.

47.

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH.

J Clin Oncol. 2007 Feb 10;25(5):540-7.

PMID:
17290063
48.

Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.

David KA, Milowsky MI, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Nanus DM, Bander NH.

Clin Genitourin Cancer. 2006 Mar;4(4):249-56. Review.

PMID:
16729907
49.

Technology insight: monoclonal antibody imaging of prostate cancer.

Bander NH.

Nat Clin Pract Urol. 2006 Apr;3(4):216-25. Review.

PMID:
16607370
50.

Antibody-based therapeutics: focus on prostate cancer.

Ross JS, Gray KE, Webb IJ, Gray GS, Rolfe M, Schenkein DP, Nanus DM, Millowsky MI, Bander NH.

Cancer Metastasis Rev. 2005 Dec;24(4):521-37. Review.

PMID:
16408160

Supplemental Content

Loading ...
Support Center